UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


           [X] Quarterly Report Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934
                  For the quarterly period ended June 30, 2000
                                       or
            [ ] Transition Report Pursuant to Section 13 or 15 (d) of
                       the Securities Exchange Act of 1934

                           Commission file No. 0-30641

                           L.A.M. PHARMACEUTICAL CORP.
                           ---------------------------
             (Exact name of registrant as specified in its charter)

             Delaware                                Applied for
        -------------------                  -------------------------
      (State of incorporation)        (I.R.S. Employer Identification Number)


                            800 Sheppard Avenue West,
                                Commercial Unit 1
                North York,, Ontario, Canada M3H 6B4 (address of
                     principal executive offices) (Zip Code)


                                 (416) 633-3004
                           --------- ----------------
              (Registrant's telephone number, including area code)




   Indicate  by check mark  whether  the  registrant:  (1) has filed all reports
   required to be filed by Section 13 or 15 (d) of the  Securities  Exchange Act
   of 1934 during the  proceeding 12 months (or for such shorter period that the
   registrant  was required to file such  reports),  and (2) has been subject to
   such filing requirements for the past 90 days.

                                 YES [X] NO [ ]


As of June 30, 2000, the Company had 10,392,500 issued and outstanding shares of
common stock.


<PAGE>




                           L.A.M. PHARMACEUTICAL CORP.

                    INTERIM CONSOLIDATED FINANCIAL STATEMENTS

                                  JUNE 30, 2000

                                   (Unaudited)






CONSOLIDATED BALANCE SHEETS

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

INTERIM CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS





<PAGE>


L.A.M. PHARMACEUTICAL, CORP.
(A DEVELOPMENT STAGE COMPANY)
(A DELAWARE CORPORATION)
Miami, Florida


TABLE OF CONTENTS
--------------------------------------------------------------------------------


Independent Accountants' Report on Interim Financial Data              F - 2

Balance Sheets at June 30, 2000 (Unaudited) and December 31, 1999      F - 3

Statements of Changes in Stockholders' Deficit for the Period
 From the Date Of Inception (February 1, 1994) Through
 June 30, 2000 (Unaudited)                                       F - 4 to F - 5

Statements of Operations for the Three Months and Six Months
 Ended June 30, 2000 and 1999 (Unaudited) and for the Period
 From the Date of Inception  (February 1, 1994)
  Through June 30, 2000 (Unaudited)                                    F - 6

Statements of Cash Flows for the Three Months and Six months
 Ended June 30, 2000 and 1999 (Unaudited) and for the Perio
 From the Date of Inception  (February 1, 1994)
  Through June 30, 2000 (Unaudited)                                    F - 7

Notes to Financial Statements                                          F - 8







<PAGE>


                         INDEPENDENT ACCOUNTANTS' REPORT


To the Board of Directors
  and Shareholders
L.A.M. Pharmaceutical, Corp.
Miami, Florida


      We have reviewed the accompanying balance sheet of L.A.M.  Pharmaceutical,
Corp.  (a  Development  Stage  Company)  as of June  30,  2000  and the  related
statements of operations,  changes in  stockholders'  deficit and cash flows for
the three  months and six months ended June 30, 2000 and 1999 and for the period
from the date of  inception  (February  1,  1994)  through  June  30,  2000,  in
accordance  with standards  established  by the American  Institute of Certified
Public Accountants.  All information  included in these financial  statements is
the representation of the Company's management.

      A review  consists  principally  of  inquiries  of Company  personnel  and
analytical procedures applied to the financial data. It is substantially less in
scope than an audit in accordance with generally  accepted  auditing  standards,
the objective of which is the  expression of an opinion  regarding the financial
statements taken as a whole. Accordingly, we do not express such an opinion.

      Based on our review, we are not aware of any material  modifications  that
should be made to the accompanying  financial statements in order for them to be
in conformity with generally accepted accounting principles.

      We have previously audited, in accordance with generally accepted auditing
standards,  the balance sheets as of December 31, 1999 and 1998, and the related
statements of operations,  changes in  stockholders'  deficit and cash flows for
the years then ended, and for the period from the date of inception (February 1,
1994)) through December 31, 1999 (presented elsewhere herein); and in our report
dated March 15, 2000,  we expressed an  unqualified  opinion on those  financial
statements.







Rotenberg & Company, LLP
Rochester, New York
  August 9, 2000



<PAGE>




L.A.M. PHARMACEUTICAL CORP.
(A DEVELOPMENT STAGE COMPANY)
(A DELAWARE CORPORATION)
Miami, Florida

BALANCE SHEETS
                                                   (Unaudited)
                                                    June 30,      December 31,
                                                      2000           1999
--------------------------------------------------------------------------------
ASSETS
Current Assets
Cash and Cash Equivalents                       $   292,406  $     558,710
Cash Held by Broker - Debentures                    362,768        465,000
Note Receivable - Debentures                         50,000         50,000
Accounts Receivable                                  75,000         75,000
Inventory - Raw Materials                            25,000             --
Investment in Affiliate                                 --              --
Prepaid Expenses                                      7,917             --
-----------------------------------------------------------------------------

Total Current Assets                                813,091      1,148,710

Property and Equipment - Net of
Accumulated Depreciation                             14,814          4,922

Other Assets
Patents and Trademarks - Net of
Accumulated Amortization                            279,226        232,417
--------------------------------------------------------------------------------
Total Assets                                     $1,107,131   $  1,386,049
================================================================================

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts Payable and Accrued Expenses           $   269,230  $     111,627
Convertible Debentures                            1,527,000      1,252,000
--------------------------------------------------------------------------

Total Current Liabilities                         1,796,230      1,363,627

Non-Current Liabilities
Due to Stockholders                               1,266,837      1,390,837
Deferred Royalty Revenue                            207,360        207,360
--------------------------------------------------------------------------

Total Liabilities                                 3,270,827      2,961,824

Stockholders' Deficit
Common               Stock - $.0001 Par;
                     50,000,000 Shares
                     Authorized; 10,392,500
                     and 10,332,500 Shares
                     Issued and Outstanding
                     as of June 30, 2000 and
                     December 31,2000,
                     Respectively                     1,039          1,039
Additional Paid in Capital                        3,713,669      3,384,823
Deficit Accumulated During Development Stage     (5,878,004)    (4,961,637)

Total Stockholders' Deficit                      (2,163,296)    (1,575,775)
---------------------------------------------------------------------------

Total Liabilities and Stockholders' Deficit   $   1,107,131   $  1,386,049
==========================================================================



    The accompanying notes are an integral part of this financial statement.


<PAGE>


L.A.M. PHARMACEUTICAL CORP.
(A DEVELOPMENT STAGE COMPANY)
(A DELAWARE CORPORATION)
Miami, Florida


STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT
For the Period From the Date of Inception (February 1, 1994) Through
June 30, 2000
--------------------------------------------------------------------------------

<TABLE>
<S>                            <C>        <C>         <C>           <C>            <C>
                                                                  Deficit
                                                                Accumulated
                                                   Additional     During          Total
                                         Common     Paid-In     Development    Stockholders
                              Shares     Stock      Capital        Stage      Equity/(Deficit)

Inception - February 1, 1994      --     $ --      $    --       $   --          $  --

Capital Contribution -
 Services Rendered                --       --       22,799           --          22,799

Capital Contribution -
 Laboratory Equipment             --       --       24,245           --          24,245

Net Loss                          --       --           --       (356,393)     (356,393)
-------------------------------------------------------------------------------------------

Balance - December 31, 1994       --       --       47,044       (356,393)     (309,349)

Capital Contribution -
 Services Rendered                --       --      172,020           --         172,020

Net Loss                          --       --           --       (522,095)     (522,095)
-------------------------------------------------------------------------------------------


Balance - December 31, 1995       --       --     219,064        (878,488)     (659,424)

Capital Contribution -
 Services Rendered                --       --     185,495             --        185,495

Capital Contribution -
 Leasehold Improvements           --       --       9,775             --          9,775

Capital Contribution -
 Interest Expense                 --       --      49,738             --         49,738

Capital Contribution in Cash      --       --      51,001             --         51,001

Net Loss                          --       --          --       (643,733)      (643,733)
-----------------------------------------------------------------------------------------
Balance December 31, 1996         --     $ --   $ 515,073    $(1,522,221)   $(1,007,148)
-----------------------------------------------------------------------------------------
Capital Contribution -
 Services Rendered                --       --     377,072             --        377,072

Capital Contribution -
 Interest Expense                 --       --      99,477             --         99,477

Capital Contribution in Cash      --       --     111,199             --        111,199

Distribution                      --       --     (30,000)            --        (30,000)

Net Loss                          --       --          --       (499,626)      (499,626)
------------------------------------------------------------------------------------------

</TABLE>

                                                                 -continued -


    The accompanying notes are an integral part of this financial statement.



<PAGE>

L.A.M. PHARMACEUTICAL CORP.
(A DEVELOPMENT STAGE COMPANY)
(A DELAWARE CORPORATION)
Miami, Florida

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT
For the Period From the Date of Inception  (February  1, 1994)  Through June 30,
2000 - Continued
<TABLE>
<S>                              <C>         <C>       <C>            <C>             <C>
                                                                      Deficit
                                                                    Accumulated
                                                      Additional      During           Total
                                             Common    Paid-In      Development    Stockholders
                                 Shares      Stock      Capital        Stage     Equity/(Deficit)
------------------------------------------------------------------------------------------------

Balance - December 31, 1997           --         --    1,072,821     (2,021,847)      (949,026)

Recapitalization as L.A.M.
  Pharmaceutical, Corp.        6,000,000        600         (600)            --             --

Capital Contribution -
  Interest Expense                    --         --      103,579             --        103,579

Issuance of Common Stock
   for Cash                    4,332,500        433      378,352             --        378,785

Distribution                          --         --      (38,660)            --       (38,660)

Net Loss Restated                     --         --           --       (458,807)     (458,807)
-----------------------------------------------------------------------------------------------

Balance - December 31, 1998 -
  Restated                    10,332,500      1,033    1,515,492     (2,480,654)     (964,129)

Capital Contribution -
  Interest Expense                    --         --      107,681             --        107,681

Issuance of Common Stock
  for Cash                        60,000          6       59,994             --         60,000

Stock Options and Awards
  Granted, Compensation for
   Services Rendered                  --         --      449,656             --        449,656

Conversion Premium on
Convertible Debentures                --         --    1,252,000             --      1,252,000

Net Loss - Restated                   --         --           --     (2,480,983)    (2,480,983)
-----------------------------------------------------------------------------------------------

 Balance - December 31, 1999 -
    Restated                   10,392,500     1,039    3,384,823     (4,961,637)    (1,575,775)

Capital Contribution -
  Interest Expense                     --        --       26,923             --         26,923

Conversion Premium on
Convertible Debentures                 --        --      265,000             --        265,000

Net Loss for the Period -
   (Unaudited) - Restated              --        --           --       (724,566)      (724,566)
-----------------------------------------------------------------------------------------------

Balance - March 31, 2000 -
   Restated                    10,392,500     1,039    3,676,746     (5,686,203)    (2,008,418)

Capital Contribution -
  Interest Expense                     --        --       26,923             --         26,923

Conversion Premium on
Convertible Debentures                 --        --       10,000             --         10,000

Net Loss for the Period -
  (Unaudited)                          --         --         --        (191,801)      (191,801)
----------------------------------------------------------------------------------------------

Balance - June 30, 2000
  (Unaudited)                  10,392,500      1,039  $3,713,669   $ (5,878,004)   $(2,163,296)
===============================================================================================
</TABLE>


        The accompanying notes are an integral part of this financial statement.



<PAGE>


L.A.M. PHARMACEUTICAL CORP.
(A DEVELOPMENT STAGE COMPANY)
(A DELAWARE CORPORATION)
Miami, Florida

STATEMENTS OF OPERATIONS
For the Three  Months  and Six Months  Ended June 30,  2000 and 1999 and for the
Period From the Date of Inception (February 1, 1994) Through June 30, 2000
<TABLE>
<S>                              <C>                  <C>            <C>            <C>             <C>
                                                                                            Date of Inception
                             (Unaudited)          (Unaudited)           (Unaudited)        (February 1, 1994)
                          Six Months Ended      Six Months Ended    Quarter Ended June 30,      Through
                            June 30, 2000       June 30, 1999       2000            1999      June 30, 2000
----------------------------------------------------------------------------------------------------------------
 Total Revenue                $     --            $    --        $     --        $    --       $  200,000
----------------------------------------------------------------------------------------------------------------
Expenses
Research and Development       163,969             58,287          22,904         14,062        1,874,768
General and Administrative     357,545            130,790         101,048         60,170        1,952,837
Interest Expense               120,376             53,846          60,188         26,923          493,795
Conversion Premium             275,000                 --          10,000             --        1,527,000
Depreciation and Amortization   13,122              3,090           8,577          1,545           40,271
------------------------------------------------------------------------------------------------------------
 Total Expenses                930,012            246,013         202,717        102,700        5,888,671
------------------------------------------------------------------------------------------------------------
Income From Operations        (930,012)          (246,013)       (202,717)      (102,700)      (5,688,671)
------------------------------------------------------------------------------------------------------------
Other Income (Expense)
Interest Income                 13,663              4,569          10,916          3,446           18,027
loss on Investment in Affiliate     --                 --              --             --         (207,360)
------------------------------------------------------------------------------------------------------------
Total Other Income (Expense)    13,663              4,569          10,916          3,446         (189,333)
------------------------------------------------------------------------------------------------------------
Net Loss                    $ (916,349)         $(241,444)     $ (191,801)     $ (99,254)     $(5,878,004)
------------------------------------------------------------------------------------------------------------
Loss Per Common Share - Basic
and Diluted                 $    (0.09)         $   (0.02)     $    (0.02)     $   (0.01)     $     (0.42)
------------------------------------------------------------------------------------------------------------
Weighted Average Number
 of Common Shares
  Outstanding               10,392,500         10,392,500       10,392,500    10,047,917
------------------------------------------------------------------------------------------------------------
</TABLE>


        The accompanying notes are an integral part of this financial statement.



<PAGE>

L.A.M. PHARMACEUTICAL CORP.
 (A DEVELOPMENT STAGE COMPANY)
 (A DELAWARE CORPORATION)
Miami, Florida

STATEMENTS OF CASH FLOWS
For the Six Months Ended June 30, 2000 and 1999 and for the Period From the Date
of Inception (February 1, 1994) Through June 30, 2000

<TABLE>
<S>                              <C>                  <C>            <C>            <C>             <C>
                                                                                                    Date of Inception
                                     (Unaudited)          (Unaudited)           (Unaudited)         (February 1, 1994)
                                  Six Months Ended      Six Months Ended    Quarter Ended June 30,       Through
                                    June 30, 2000       June 30, 1999       2000            1999       June 30, 2000
----------------------------------------------------------------------------------------------------------------------
Cash Flows from Operating Activities

Net Loss                             $ (916,349)         $ (241,444)    $(191,801)      $(99,254)      $(5,878,004)
Adjustments to Reconcile Net Loss to
  Net Cash Flows From Operating Activities:
    Depreciation and Amortization        13,122               3,090         8,597          1,545            55,942
    Capital Contributions:
      Services including Stock Options       --                 --             --             --         1,207,042
   Interest Expense                      87,111             53,846         26,923         26,293           414,321
   Conversion Premium on Debenture      275,000                 --         10,000             --         1,527,000
   Loss on Investment in Affiliate           --                 --             --             --           207,360
  Changes in Assets and Liabilities:
    Accounts Receivable                      --                 --             --             --           (75,000)
    Inventory - Raw Materials           (25,000)                --        (25,000)            --           (25,000)
    Prepaid Expenses                     (7,917)                --         22,083             --            (7,917)
    Accounts Payable and Accrued
      Expenses                          124,338            107,213        121,594         51,012           269,230
    Due to Stockholders                (124,000)                --       (124,000)            --         1,266,837
    Other                                    --              1,820           (467)         3,689                 8
---------------------------------------------------------------------------------------------------------------------
Net Cash Flows from Operating
   Activities                          (573,695)           (75,475)      (152,071)      (16,715)        (1,038,181)
---------------------------------------------------------------------------------------------------------------------
Cash Flows from Investing Activities
  Equipment                             (14,942)                --         (1,738)           --            (20,028)
  Patents and Trademarks                (54,899)                --             --       (71,859)          (295,942)
---------------------------------------------------------------------------------------------------------------------
Net Cash Flows from Investing
   Activities                           (69,841)                --         (1,738)       (71,859)         (315,970)
---------------------------------------------------------------------------------------------------------------------
Cash Flows from Financing Activities
  Cash Capital Contributions                 --                 --             --            --            162,200
  Proceeds from Issuance of Common Stock     --                 --             --            --            438,785
    Proceeds from Convertible
        Debentures                      275,000           (125,000)        10,000            --          1,477,000
  Distributions to Stockholders              --                 --             --            --           (68,660)
---------------------------------------------------------------------------------------------------------------------
Net Cash Flows from Financing
   Activities                           275,000           (125,000)        10,000            --          2,009,325
---------------------------------------------------------------------------------------------------------------------
Net Increase in Cash and Cash
   Equivalents                         (368,536)          (200,475)      (143,809)      (88,574)           655,174

Cash and Cash Equivalents - Beginning
  of Period                           1,023,710            410,577        798,983       298,676                 --
--------------------------------------------------------------------------------------------------------------------
Cash and Cash Equivalents - End
   of Period                            655,174            210,102     $  655,174     $ 210,102         $  655,174
---------------------------------------------------------------------------------------------------------------------
NON-CASH INVESTING AND FINANCING ACTIVITIES
Issuance of Common Stock in Exchange
    for Property and Equipment                                         $       --     $      --         $   34,020
Investment in Affiliate                                                                                 $  207,360
Deferred Revenue                                                                                        $  207,360
---------------------------------------------------------------------------------------------------------------------
</TABLE>


        The accompanying notes are an integral part of this financial statement.


<PAGE>


L.A.M. PHARMACEUTICAL, CORP.
(A DEVELOPMENT STAGE COMPANY)
(A DELAWARE CORPORATION)
Miami, Florida


NOTES TO FINANCIAL STATEMENTS
-------------------------------------------------------------------------------


Note A -  Basis of Presentation

        The condensed financial statements of L.A.M. Pharmaceutical,  Corp. (the
        "Company")  included  herein have been prepared by the Company,  without
        audit,  pursuant  to the rules and  regulations  of the  Securities  and
        Exchange  Commission  (the  "SEC").  Certain  information  and  footnote
        disclosures  normally  included  in  financial  statements  prepared  in
        conjunction  with generally  accepted  accounting  principles  have been
        condensed or omitted  pursuant to such rules and  regulations,  although
        the  Company  believes  that the  disclosures  are  adequate to make the
        information   presented  not  misleading.   These  condensed   financial
        statements  should  be read  in  conjunction  with  the  annual  audited
        financial  statements and the notes thereto included elsewhere herein in
        the Company's registration statement on Form 10SB.

        The accompanying  unaudited  interim  financial  statements  reflect all
        adjustments  of a normal and recurring  nature which are, in the opinion
        of  management,  necessary  to present  fairly the  financial  position,
        results of  operations  and cash flows of the  Company  for the  interim
        periods  presented.  The results of operations for these periods are not
        necessarily  comparable  to,  or  indicative  of,  results  of any other
        interim  period of for the calendar year taken as a whole.  Factors that
        affect the  comparability  of  financial  data from year to year and for
        comparable  interim periods include  non-recurring  expenses  associated
        with  the  Company's  registration  with  the  Securities  and  Exchange
        Commission  and costs  incurred  to raise  capital and  acquisitions  of
        patents and trademarks.










<PAGE>


Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

      This  Quarterly  Report on Form 10-QSB  contains  certain  statements of a
forward-looking  nature  relating  to  future  events  or the  future  financial
performance of the Company.  Such statements are only predictions and the actual
events or results may differ materially from the actual results discussed in the
forward-looking  statements.  Factors  that could  cause or  contribute  to such
differences  include those  discussed  below as well as those discussed in other
filings  made by the  Company  with  the  Securities  and  Exchange  Commission,
including the Company's Registration Statement on Form-10SB.

Results of Operations

Three months ended June 30, 2000  compared  with the three months ended June 30,
1999

Expenses

Research and Development

      Research and development  expenses were $22,904 for the three months ended
June 30, 2000 as compared to $14,062 for the three  months  ended June 30, 1999.
The increase was attributable to the timing of clinical studies conducted during
the first quarter of 2000.

General and Administrative

      General and administrative costs increased by $40,878 from $60,170 for the
three months ended June 30, 1999 to $101,048 for the three months ended June 30,
2000. The increase in general and  administrative  costs was attributable to the
Company's efforts in raising capital, restructuring its business activities, and
registering the Company's common stock.

Interest Expense

      Interest  expense for the three  months  ended June 30, 2000  increased by
$33,265 to $60,188 as compared  with $26,923 for the three months ended June 30,
1999.  The  increase  represents  the  interest  accrued  for the quarter on the
convertible  debentures  that were issued during the second half of 1999 and the
first quarter of 2000.

Depreciation and Amortization

      Depreciation  and  amortization  increased  by $7,032  from $1,545 for the
three  months ended June 30, 1999 to $8,577 for the three months ended March 31,
2000.  The  increase  was due  primarily  to the  amortization  of  patents  and
trademarks acquired during 1999.



<PAGE>


Other Income

      Other income, which was comprised only of interest income, was $10,916 for
the three  months  ended June 30,  2000 as  compared  with  $3,446 for the three
months ended June 30,  1999.  The  increase  was  attributed  to the increase in
invested  cash as a result of the  debentures  that were issued during the later
half of 1999 and the first quarter of 2000.

Six months ended June 30, 2000 compared with the six months ended June 30, 1999

Expenses

Research and Development

      Research and development  expenses  increased by $105,682 from $58,287 for
the six months ended June 30, 1999 to $163,969 for the six months ended June 30,
2000. The increase was  attributable to the increased  activities as a result of
the cash available from issuance of the debentures in the later half of 1999 and
first quarter 2000.

General and Administrative Costs

      General and  administrative  costs increased by $226,755 from $130,790 for
the six months ended June 30, 1999 to $357,545 for the six months ended June 30,
2000. The increase in general and  administrative  costs was attributable to the
Company's efforts in raising capital, restructuring its business activities, and
registering the Company's common stock.

Interest Expense

      Interest  expense  for the six months  ended June 30,  2000  increased  by
$66,530 to $120,376 as compared  with  $53,846 for the six months ended June 30,
1999. The increase  represents the interest  accrued for the six month period on
the  convertible  debentures that were issued during the second half of 1999 and
the first quarter of 2000.

Depreciation and Amortization

      Depreciation and amortization increased by $10,052 from $3,090 for the six
months  ended June 30, 1999 to $13,142 for the six months  ended June 30,  2000.
The increase was due  primarily to the  amortization  of patents and  trademarks
acquired during 1999.

Other Income

      Other income, which was comprised only of interest income, was $13,663 for
the six months  ended June 30, 2000 as  compared  with $4,569 for the six months
ended June 30, 1999.  The increase  was  attributed  to the increase in invested
cash as a result of the convertible debentures that were issued during the later
half of 1999 and the first quarter of 2000.



<PAGE>


Liquidity and Sources of Capital

      During the six months ended June 30, 2000 the  Company's  operations  used
approximately  $574,000 in cash and the Company spent  approximately  $70,000 on
patent and trademark applications and purchases of equipment.  Cash required for
operations during the six months ended June 30, 2000 was generated through sales
of convertible  notes of $275,000.  The Company's primary source of liquidity at
June 30, 2000 was $655,174 in cash accounts.

      During the remainder of fiscal year 2000, the Company expects that it will
spend  between  $110,000  and $150,000 on  research,  development,  and clinical
studies.  As of June 30, 2000 the Company had working  capital of  approximately
$577,000  (exclusive  of the  convertible  debentures  that are  expected  to be
converted to equity and liabilities  due to  shareholders  of the Company).  The
Company  plans to use its existing  financial  resources as well as the proceeds
from the sale of its common stock to fund its capital  requirements  during this
period.  The  Company  does not have any  commitments  from any  third  party to
provide any capital to the Company.  It should be noted that  substantial  funds
may be needed for more  extensive  research  and clinical  studies  which may be
necessary  before  the  Company  will be able to sell any of its  products  on a
commercial basis.

      Other than funding its research and  development  activities and operating
losses, the Company does not have any material capital commitments.

      All of the Company's  products are in the development  stage. As a result,
the  Company  has not  generated  any  revenues  from the sale of its  products.
Revenues  since its inception  has been limited to payments  received from Ixora
for expense reimbursements and interest income on invested cash balances.

      Due to the lack of any significant  revenues,  the Company has relied upon
proceeds  realized  from the public  and  private  sale of its common  stock and
convertible notes to meet its funding requirements.  Funds raised by the Company
have been  expended  primarily in  connection  with  research  and  development,
clinical studies and administrative costs. Since the Company does not anticipate
realizing  revenues  until  such time as it begins  the  commercial  sale of its
products or enters into licensing  arrangements  regarding these products (which
could take a number of years), the Company will be required, through the sale of
securities,  debt  financing  or other  arrangements,  to fund  its  operations.
However,  there can be no assurance  that such financing will be available or be
available on favorable terms.

      Since  its   inception  in  1994  the  Company  has  incurred   losses  of
$(5,878,004). The Company expects to incur additional losses for the foreseeable
future,  and the  Company's  losses could  increase as research and  development
efforts progress.



<PAGE>


                                     PART II
                                OTHER INFORMATION



Item 6.  Exhibits and Reports on Form 8-K

(a)   Exhibits

        Exhibit 27 - Financial Data Schedule

(b)   Reports on Form 8-K

      The Company did not file any reports on Form 8-K during the quarter ending
June 30, 2000.




<PAGE>




                                   SIGNATURES

Pursuant to the  requirements  of Section 12 of the  Securities  Exchange Act of
1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized


                           L.A.M. PHARMACEUTICAL CORP.



                              By:  /s/ Alan Drizen
                                   Alan Drizen, Chief Executive Officer


                              Date:     August 16, 2000